Projects per year
Abstract / Description of output
Mechanistically, TLR2 impairs early lung cancer progression via activation of cell intrinsic cell cycle arrest pathways and the proinflammatory senescence-associated secretory phenotype (SASP). The SASP regulates non-cell autonomous anti-tumor responses such as immune surveillance of premalignant cells, and we observe impaired myeloid cell recruitment to lung tumors following Tlr2 loss. Lastly, we show that administration of a TLR2 agonist reduces lung tumor growth, highlighting TLR2 as a possible therapeutic target.
FingerprintDive into the research topics of 'Toll-like receptor orchestrates a tumor suppressor response in non-small cell lung cancer'. Together they form a unique fingerprint.
1/08/17 → 31/07/25
1/10/18 → 30/09/20